A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults

Principle Instigator
Prof. Omu Anzala
Abstract

Objective To evaluate the safety and tolerability of intramuscular administration of the HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in HIV-uninfected adults